COX-2-IN-31 

COX-2-IN-31 (compound 7b) is an orally active and dual inhibitor of COX-2 (IC₅₀=60 nM) and 5-LOX (IC₅₀=1.9 μM). COX-2-IN-31 also inhibits transmembrane hCA IX(K_i=48.9 nM) and hCA XII(K_i=5.8 nM) activity. COX-2-IN-31 exhibits anti-inflammatory and analgesic activity^[1].

COX-2-IN-31 (compound 7b) potently inhibits hCA IX and XII with Ki values in the nanomolar range(48.9 nM and 5.8 nM) in the Carbonic anhydrase inhibition assay^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

COX-2-IN-31 (compound 7b) (10 mg/kg; oral gavage; single dose) exhibits analgesic activity, meanwhile it results a significant reduction in the number of writhing in Acetic acid writhing test^[1].
COX-2-IN-31 (10 mg/kg; oral gavage; single dose) results a significant reduction of paw height in Carrageenan (HY-125474)-induced rat paw edema assay^[1].
COX-2-IN-31 (10 mg/kg; p.o; single dose) shows safety profile on the gastric tissues in male albino rats^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

400.41

C₁₇H₁₆N₆O₄S

NC1=C(C=NN1C2=CC=C(C=C2)S(N)(=O)=O)C(N/N=C/C3=CC=C(C=C3)O)=O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Ragab MA, et al. 4-(5-Amino-pyrazol-1-yl) benzene sulfonamide derivatives as novel multi-target anti-inflammatory agents endowed with inhibitory activity against COX-2, 5-LOX and carbonic anhydrase: Design, synthesis, and biological assessments. Eur J Med Chem. 2023 Mar 15; 250:115180.  [Content Brief]